국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
Tulathromycin
Dopharma Research B.V.
QJ01FA94
Tulathromycin
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
tulathromycin
Authorised
2022-01-07
Health Products Regulatory Authority 11 January 2022 CRN009YR1 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT DORAXX 25 mg/ml solution for injection for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Tulathromycin 25 mg EXCIPIENT: Monothioglycerol 5 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear colourless to slightly yellow solution, free from visible particles. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment and metaphylaxis of swine respiratory disease (SRD) associated with _Actinobacillus pleuropneumoniae_, _Pasteurella _ _multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis _and _Bordetella bronchiseptica _susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used. The veterinary medicinal product should only be used if pigs are expected to develop the disease within 2–3 days. 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to macrolide antibiotics or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Cross resistance occurs with other macrolides. Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to tulathromycin and may decrease the effectiveness of tre 전체 문서 읽기